

Jose Maria Abascal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1616729/jose-maria-abascal-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

533
citations

12
h-index

23
g-index

30
ext. papers

599
ext. citations

2.3
avg, IF

2.55
L-index

#	Paper	IF	Citations
19	Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 11	3	9
18	Síndrome de Zinner en paciente afecto de síndrome de Kallmann: rara asociación de 2 malformaciones embrionarias. <i>Revista Internacional De Andrología</i> , 2016 , 14, 144-147	0.6	
17	Retroperitoneal and transperitoneal laparoscopic cryotherapy for small renal masses. <i>Actas Urológicas Españolas</i> , 2015 , 39, 582-7	0.7	
16	Effectiveness of hexaminolevulinat fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. <i>BJU International</i> , 2015 , 116, 37-43	5.6	22
15	Repeated spurious elevation of serum prostate-specific antigen values solved by chemiluminescence analysis: A possible interference by heterophilic antibodies. <i>Korean Journal of Urology</i> , 2015 , 56, 785-7		
14	Retroperitoneal laparoscopic cryotherapy in bilateral, synchronous kidney tumor. <i>Actas Urológicas Españolas</i> , 2013 , 37, 453-5	0.7	2
13	Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010. <i>BJU International</i> , 2012 , 110, E701-6	5.6	31
12	Experiencia y resultados en la suprarrenalectomía laparoscópica transperitoneal. <i>Actas Urológicas Españolas</i> , 2010 , 34, 412-416	0.7	4
11	Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. <i>Urology</i> , 2007 , 69, 500-4	1.6	127
10	Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. <i>Urologia Internationalis</i> , 2006 , 77, 135-8	1.9	55
9	Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. <i>Journal of Urology</i> , 2006 , 175, 1679-83; discussion 1683	2.5	80
8	Correlation between the biopsies in marginal donor kidneys for transplantation: is it necessary to biopsy both kidneys?. <i>Transplantation Proceedings</i> , 2006 , 38, 1270-3	1.1	4
7	Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma. <i>International Urology and Nephrology</i> , 2006 , 38, 463-5	2.3	5
6	Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. <i>International Journal of Biological Markers</i> , 2005 , 20, 209-16	2.8	15
5	Gastric cancer in augmentation gastrocystoplasty. <i>Urologia Internationalis</i> , 2005 , 74, 368-70	1.9	20
4	Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. <i>International Journal of Cancer</i> , 2004 , 108, 877-81	7.5	45
3	Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. <i>European Urology</i> , 2003 , 44, 661-5	10.2	49

- 2 The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. *European Urology*, **2002**, 42, 333-7 10.2 13
- 1 Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. *International Journal of Biological Markers*, **2002**, 17, 239-43 2.8 2